StockNews.com started coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a report issued on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, William Blair cut shares of Pieris Pharmaceuticals from an outperform rating to a market perform rating in a research report on Wednesday, June 21st. […]
William Blair downgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) from an outperform rating to a market perform rating in a report released on Wednesday, PriceTargets.com reports. Separately, StockNews.com started coverage on Pieris Pharmaceuticals in a research report on Thursday, May 18th. They set a hold rating for the company. Pieris Pharmaceuticals Stock Up […]
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) is set to announce its earnings results after the market closes on Tuesday, May 9th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link. Pieris Pharmaceuticals Stock […]
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) shares passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $1.12 and traded as low as $0.72. Pieris Pharmaceuticals shares last traded at $0.74, with a volume of 755,081 shares changing hands. Wall Street Analysts Forecast […]
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) – Analysts at William Blair cut their Q1 2023 earnings per share estimates for shares of Pieris Pharmaceuticals in a research note issued on Wednesday, November 2nd. William Blair analyst M. Phipps now anticipates that the biotechnology company will earn ($0.16) per share for the quarter, down from […]